Yorktown Management & Research Co Inc Buys New Position in TG Therapeutics, Inc. $TGTX

Yorktown Management & Research Co Inc bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 10,650 shares of the biopharmaceutical company’s stock, valued at approximately $383,000.

Several other institutional investors and hedge funds also recently made changes to their positions in TGTX. Wellington Management Group LLP boosted its position in shares of TG Therapeutics by 1,809.9% during the 1st quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock valued at $47,830,000 after purchasing an additional 1,149,526 shares in the last quarter. Driehaus Capital Management LLC bought a new stake in shares of TG Therapeutics during the 1st quarter valued at about $30,545,000. Nuveen LLC bought a new stake in shares of TG Therapeutics during the 1st quarter valued at about $29,442,000. Woodline Partners LP bought a new stake in shares of TG Therapeutics during the 1st quarter valued at about $21,021,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of TG Therapeutics by 21.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after purchasing an additional 345,059 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Up 2.6%

Shares of NASDAQ:TGTX opened at $34.55 on Wednesday. The stock has a market cap of $5.48 billion, a price-to-earnings ratio of 93.38 and a beta of 1.97. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a 12-month low of $22.92 and a 12-month high of $46.48. The business’s 50 day moving average is $33.13 and its 200 day moving average is $34.92.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.15). The company had revenue of $141.15 million for the quarter, compared to analysts’ expectations of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm’s quarterly revenue was up 92.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TGTX. HC Wainwright began coverage on TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. B. Riley upped their price target on TG Therapeutics from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. Finally, The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 price target on the stock in a research note on Thursday, July 10th. Three equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.75.

Insider Activity

In related news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the transaction, the director owned 94,061 shares of the company’s stock, valued at $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.64% of the stock is currently owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.